Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations.
暂无分享,去创建一个
Stefan Fröhling | Lars Bullinger | Claudia Scholl | Hartmut Döhner | Konstanze Döhner | S. Fröhling | L. Bullinger | K. Döhner | R. Schlenk | H. Döhner | C. Scholl | F. Rücker | Frank G Rücker | Andrea Corbacioglu | Richard F Schlenk | Marianne Habdank | A. Corbacioglu | Marianne Habdank | F. Rücker | Stefan Fröhling | H. Döhner | Konstanze Döhner
[1] Frank E. Harrell,et al. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .
[2] H. Dombret,et al. A white blood cell index as the main prognostic factor in t ( 8 ; 21 ) acute myeloid leukemia ( AML ) : a survey of 161 cases from the French AML Intergroup , 2002 .
[3] G. Ehninger,et al. Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .
[4] D N Shapiro,et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. , 1994, Science.
[5] S. Galimberti,et al. Interferon-α activity in a case of severe autoimmune lymphoproliferative disease , 2001, Annals of Hematology.
[6] S. Raimondi,et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. , 1996, Oncogene.
[7] C. Lehner,et al. Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.
[8] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[9] Pier Paolo Pandolfi,et al. NPM mutations in acute myelogenous leukemia. , 2005, The New England journal of medicine.
[10] H. Dombret,et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. , 2003, Blood.
[11] H. F. Horn,et al. Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication , 2000, Cell.
[12] S. Corey,et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. , 1996, Blood.
[13] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[14] K. Pulford,et al. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis , 1997, Molecular and cellular biology.
[15] M. Caligiuri,et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. , 2001, Cancer research.
[16] S. Fröhling,et al. Comparison of cytogenetic and molecular cytogenetic detection of chromosome abnormalities in 240 consecutive adult patients with acute myeloid leukemia. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Pier Giuseppe Pelicci,et al. Nucleophosmin regulates the stability and transcriptional activity of p53 , 2002, Nature Cell Biology.
[18] J. Cayuela,et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). , 2002, Blood.
[19] S. Fröhling,et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] B Falini,et al. Detection of normal and chimeric nucleophosmin in human cells. , 1999, Blood.
[21] M. Olson,et al. Mapping the Functional Domains of Nucleolar Protein B23* , 2000, The Journal of Biological Chemistry.
[22] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[23] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[24] M. Olson,et al. Nucleolar protein B23 has molecular chaperone activities , 2008, Protein science : a publication of the Protein Society.
[25] J. Weber,et al. ARF Impedes NPM/B23 Shuttling in an Mdm2-Sensitive Tumor Suppressor Pathway , 2004, Molecular and Cellular Biology.
[26] H. Umekawa,et al. Tryptophans 286 and 288 in the C-terminal Region of Protein B23.1 are Important for Its Nucleolar Localization , 2002, Bioscience, biotechnology, and biochemistry.
[27] M. Olson,et al. Preribosomal ribonucleoprotein particles are a major component of a nucleolar matrix fraction. , 1986, Biochemistry.
[28] Bob Löwenberg,et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. , 2003, The hematology journal : the official journal of the European Haematology Association.
[29] M. Valentine,et al. Sequence Correction , 1995, Science.
[30] B. Pulendran,et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. , 2000, Blood.
[31] S. Fröhling,et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] S. Usui,et al. The carboxyl terminal sequence of nucleolar protein B23.1 is important in its DNA polymerase alpha-stimulatory activity. , 2001, Journal of biochemistry.
[33] D. Gilliland,et al. Genetics of myeloid leukemias. , 2003, Annual review of genomics and human genetics.
[34] M. Wu,et al. Evidence for the ability of nucleophosmin/B23 to bind ATP. , 1998, The Biochemical journal.
[35] B. Falini,et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. , 2005, Blood.
[36] S. Fröhling,et al. Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial , 2003, Leukemia.
[37] Natalia Meani,et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. , 2005, Blood.
[38] Iscn. International System for Human Cytogenetic Nomenclature , 1978 .
[39] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[40] C. Bloomfield,et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. , 1998, Cancer research.
[41] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] E. Korn. Censoring distributions as a measure of follow-up in survival analysis. , 1986, Statistics in medicine.
[43] Axel Benner,et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. , 2002, Blood.